テネシーにおける乳がんの臨床試験
テネシー内の拠点で、乳がんに関する91件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sarah Cannon Research Institute, Nashville
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- The West Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Sarah Cannon Research Institute (Nashville), Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Scri Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06120283IKS014 in Advanced Solid Tumors That Express HER2
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05872295A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07060807A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- West Cancer Center, Germantown
被験者募集中第2相
18歳以上 · 女性 · 2026/09/25更新 · NCT07054190A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Tennessee Cancer Specialists ( Site 7001), Knoxville
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Baptist Memorial Healthcare, Memphis
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chattanooga
- Research Site, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05523947A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Bartlett
- Clinical Trial Site, Knoxville
- Clinical Trial Site, Mount Juliet
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- West Cancer Center, Germantown
- Vanderbilt, Nashville
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Tennessee Oncology, Nashville
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07287098A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 女性 · 2026/09/21更新 · NCT07524855ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- The West Clinic, P.C. dba West Cancer Center, Germantown
- Tennessee Oncology, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Baptist Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga
- The West Clinic, Germantown
- Tennessee Oncology PLLC, Nashville
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT03424005Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- SCRI Oncology Partners ( Site 7000), Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
- The West Clinic, PC dba West Cancer Center, Germantown
被験者募集中
70歳以上 · 全性別 · 2026/09/09更新 · NCT07629206A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06440005Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05386108A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Nashville
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/08更新 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Tennessee Cancer Specialists, Knoxville
- Tennessee Oncology, PLLC, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Nashville General, Nashville
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。